At the news
? MIXEDIMPACT 7/10 PRESS-RELEASE filed Nov 9, 2026 at 07:15 ET
CorMedix (CRMD) will acquire substantially all of Heron Therapeutics' (HRTX) assets for $145M cash plus 14.6M CRMD shares (worth ~$77.6M at signing), plus up to $55M in earn-outs and royalties. The deal adds four commercial-stage hospital products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL) to CorMedix's institutional platform. Heron will remain a public company with CRMD stock, NOLs (~$2.3B), and earn-out rights, while repaying its Hercules credit facility. The transaction is expected to close in Q1 2027.
- Upfront consideration: $145M cash plus 14,583,333 shares of CorMedix common stock (fixed at $7.20/share, valued at ~$77.6M at CRMD's $5.32 closing price on Nov 6, 2026), aggregate ~$222.6M
- Additional earn-out: up to $55M tied to ZYNRELEF 2028 net sales ($25M if ≥$65M, +$30M if ≥$95M)
- 5% royalty on combined annual net sales of CINVANTI, SUSTOL, and licensed products exceeding $25M in 2027-2029
- CorMedix expects $45-$60M in near-term operating cost synergies by year-end 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access